chemical composition of KYNAMRO in the United States, Australia, SouthAfrica, India, Japan and the
European Union. The issued U.S. claims should protect KYNAMRO from generic competition in the United
States until at least 2025. We are also pursuing additional patent applications designed to protect KYNAMRO in
these and other jurisdictions including Canada. The table below lists the key issued patent claims designed to
protect KYNAMRO in the applicable jurisdiction:
Jurisdiction
Patent No.
Title
Expiration
Description of Claims
United States
7,407,943
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2021
Methods of inhibiting expression of apoB,
decreasing serum cholesterol, decreasing
lipoprotein levels, decreasing serum
triglycerides in a human with an antisense
compound 12 to 30 nucleotide in length
and 100% complementary to human apoB
wherein the compound is not a ribozyme.
Australia
2002-326481 ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2021
An isolated oligonucleotide compound 12
to 30 nucleobases in length 100%
complementary to at least a 12-nucleobase
portion of a nucleic acid molecule having
nucleotides 151-12820 of SEQ ID 3 (apoB)
which is not a ribozyme and use of such
compound in therapy
Japan
4471650
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2021
Use of an antisense oligonucleotide 12 to
30 nucleobases in length and 100%
complementary to human apoB having one
or more modifications and inhibiting
expression of apoB by at least 90% in
primary hepatocytes when present at a
concentration of 300 nM for preparation of
a medicament for decreasing serum
cholesterol, and decreasing lipoprotein
levels in a human
United States
7,511,131
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2025
Antisense sequence and composition of
matter of KYNAMRO
Europe
EP1569695
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2023
Antisense sequence and composition of
matter of KYNAMRO
Europe
EP2336318
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2023
Antisense sequence and composition of
matter of KYNAMRO
India
219847
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2023
Antisense sequence and composition of
matter of KYNAMRO
Australia
2003294281
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2023
Antisense sequence and composition of
matter of KYNAMRO
SouthAfrica
2005/03690
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2023
Antisense sequence and composition of
matter of KYNAMRO
Japan
4986109
ANTISENSEMODULATIONOF
APOLIPOPROTEINB
EXPRESSION
2023
Antisense sequence and composition of
matter of KYNAMRO
46
